» Articles » PMID: 21604071

Distinct Myeloid Suppressor Cell Subsets Correlate with Plasma IL-6 and IL-10 and Reduced Interferon-alpha Signaling in CD4⁺ T Cells from Patients with GI Malignancy

Overview
Date 2011 May 24
PMID 21604071
Citations 84
Authors
Affiliations
Soon will be listed here.
Abstract

Interferon-alpha (IFN-α) promotes anti-tumor immunity through its actions on immune cells. We hypothesized that elevated percentages of myeloid-derived suppressor cells (MDSC) and increased pro-inflammatory cytokines in peripheral blood would be associated with impaired response to IFN-α in patients with gastrointestinal (GI) malignancies. This study evaluated relationships between plasma IL-6, IL-10, circulating MDSC subsets, and IFN-α-induced signal transduction in 40 patients with GI malignancies. Plasma IL-6 and IL-10 were significantly higher in patients versus normal donors. CD33(+)HLADR(-)CD11b(+)CD15(+) and CD33(+)HLADR(-/low)CD14(+) MDSC subsets were also elevated in patients versus normal donors (P < 0.0001). Plasma IL-6 was correlated with CD33(+)HLADR(-)CD15(+) MDSC (P = 0.008) and IL-10 with CD33(+)HLADR(-)CD15(-) MDSC (P = 0.002). The percentage of CD15(+) and CD15(-) but not CD14(+) MDSC subsets were inversely correlated with IFN-α-induced STAT1 phosphorylation in CD4(+) T cells, while co-culture with in vitro generated MDSC led to reduced IFN-α responsiveness in both PBMC and the CD4(+) subset of T cells from normal donors. Exploratory multivariable Cox proportional hazards models revealed that an increased percentage of the CD33(+)HLADR(-)CD15(-) MDSC subset was associated with reduced overall survival (P = 0.049), while an increased percentage of the CD33(+)HLADR(-/low)CD14(+) subset was associated with greater overall survival (P = 0.033). These data provide evidence for a unique relationship between specific cytokines, MDSC subsets, and IFN-α responsiveness in patients with GI malignancies.

Citing Articles

Factors Influencing Immunotherapy Outcomes in Cancer: Sarcopenia and Systemic Inflammation.

Ucgul E, Guven D, Ucgul A, Ozbay Y, Onur M, Akin S Cancer Control. 2024; 31:10732748241302248.

PMID: 39547932 PMC: 11569492. DOI: 10.1177/10732748241302248.


Neutrophil-like Monocytes Increase in Patients with Colon Cancer and Induce Dysfunctional TIGIT+ NK Cells.

Calabro A, Drommi F, Sidoti Migliore G, Pezzino G, Vento G, Freni J Int J Mol Sci. 2024; 25(15).

PMID: 39126041 PMC: 11313383. DOI: 10.3390/ijms25158470.


Dynamics and cytokinic regulation of immune cell infiltration in genetically engineered mouse models of pancreatic cancer dictate the sensitivity to immunotherapy.

Safak O, Wang S, Reyes C, Gurcinar I, Tokalov S, Cevik N Cancer Commun (Lond). 2023; 44(1):178-182.

PMID: 37877813 PMC: 10794007. DOI: 10.1002/cac2.12496.


Dendritic Cell Vaccination in Non-Small Cell Lung Cancer: Remodeling the Tumor Immune Microenvironment.

Abascal J, Oh M, Liclican E, Dubinett S, Salehi-Rad R, Liu B Cells. 2023; 12(19).

PMID: 37830618 PMC: 10571973. DOI: 10.3390/cells12192404.


BTK inhibition potentiates anti-PD-L1 treatment in murine melanoma: potential role for MDSC modulation in immunotherapy.

Sun S, Angell C, Savardekar H, Sundi D, Abood D, Benner B Cancer Immunol Immunother. 2023; 72(11):3461-3474.

PMID: 37528320 PMC: 10592087. DOI: 10.1007/s00262-023-03497-1.


References
1.
Poschke I, Mougiakakos D, Hansson J, Masucci G, Kiessling R . Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res. 2010; 70(11):4335-45. DOI: 10.1158/0008-5472.CAN-09-3767. View

2.
Strohlein M, Heiss M . Intraperitoneal immunotherapy to prevent peritoneal carcinomatosis in patients with advanced gastrointestinal malignancies. J Surg Oncol. 2009; 100(4):329-30. DOI: 10.1002/jso.21338. View

3.
Biron C . Interferons alpha and beta as immune regulators--a new look. Immunity. 2001; 14(6):661-4. DOI: 10.1016/s1074-7613(01)00154-6. View

4.
Jaffee E, Hruban R, Biedrzycki B, Laheru D, Schepers K, Sauter P . Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol. 2001; 19(1):145-56. DOI: 10.1200/JCO.2001.19.1.145. View

5.
Le Bon A, Durand V, Kamphuis E, Thompson C, Bulfone-Paus S, Rossmann C . Direct stimulation of T cells by type I IFN enhances the CD8+ T cell response during cross-priming. J Immunol. 2006; 176(8):4682-9. DOI: 10.4049/jimmunol.176.8.4682. View